Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers
Afatinib plus capecitabine is tolerable but does not have clinically meaningful efficacy in refractory PDA/BTC. Future studies should test novel anti-EGFR/HER2 therapies in <i>KRAS</i><sup>WT</sup> cancers further selected with a comprehensive molecular profile.
Authors
- Bryan P. Schneider (ORCID: https://orcid.org/0000-0003-1868-7739)
- Eric Quentin Konnick (ORCID: https://orcid.org/0000-0001-5904-1788)
- Veena Shankaran (ORCID: https://orcid.org/0000-0001-8136-6140)
- E. Gabriela Chiorean
- Sita Kugel (ORCID: https://orcid.org/0000-0001-7202-187X)
- Reina Hibbert
- Kelsey K. Baker (ORCID: https://orcid.org/0000-0002-8062-8839)
- Mary W. Redman (ORCID: https://orcid.org/0000-0003-2294-9674)
- Jeniece Hensel
- Rachael A. Safyan (ORCID: https://orcid.org/0000-0002-0181-6007)
- Andrew L. Coveler (ORCID: https://orcid.org/0000-0003-1710-5637)
- Stacey A. Cohen (ORCID: https://orcid.org/0000-0002-6207-9856)
- Anne Younger
- Colin C. Pritchard (ORCID: https://orcid.org/0000-0002-2461-1557)
- Annie Alidina (ORCID: https://orcid.org/0009-0008-1572-645X)
- Greg Andrew Durm (ORCID: https://orcid.org/0000-0003-2606-745X)
- Gentry Teng King (ORCID: https://orcid.org/0000-0002-7525-8802)
- Hannah H. Lee
- David B. Zhen (ORCID: https://orcid.org/0000-0003-3375-5912)
- Safi Shahda
- Eric A. Collisson (ORCID: https://orcid.org/0000-0002-2829-355X)
- William Proctor Harris
- Yvonne C. LaFary
Institutions
- Indiana University Health (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Intellia Therapeutics (United States) (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3390/cancers17111830
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fred Hutchinson Cancer Research Center